Quincy Antoine Quick
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Quincy Antoine Quick has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Elahe Mahdavian
Department of Biological Science LSU Shreveport, One University Place Shreveport Louisiana USA
2 shared publications - Fatima- Tuz- Zahra
TIGER Institute, Tennessee State University, Nashville, TN 37209, USA
2 shared publications - Richard Mu
TIGER Institute, Tennessee State University, Nashville, TN 37209, USA
2 shared publications Toral Mehta
Department of Biological Sciences, Tennessee State University, Nashville, TN, USA
2 shared publications- Adeolu Oluwaseun Ajayi
Department of Industrial Engineering and Operations Research, Columbia University in the City of New York, New York, NY 10027, USA
1 shared publication Anthony Okechukwu Ejiofor
Department of Biological Sciences, Tennessee State University, Nashville, TN 37209, USA
1 shared publication
Latest Publications
- Open Access
Optimization of Electrospinning Parameters for Lower Molecular Weight Polymers: A Case Study on Polyvinylpyrrolidone
Polyvinylpyrrolidone (PVP) is a synthetic polymer that holds significance in various fields such as biomedical, medical, and electronics, due to its biocompatibility and exceptional dielectric properties. Electrospinning is the most commonly used tool to fabricate fibers because of its convenience and the wide choice of parameter optimization. Various parameters, including solution molarity, flow rate, voltage, needle gauge, and needle-to-collector distance, can be optimized to obtain the desired morphology of the fibers. Although PVP is commercially available in various molecular weights, PVP with a molecular weight of 130,000 g/mol is generally considered to be the easiest PVP to fabricate fibers with minimal challenges. However, the fiber diameter in this case is usually in the micron regime, which limits the utilization of PVP fibers in fields that require fiber diameters in the nano regime. Generally, PVP with a lower molecular weight, such as 10,000 g/mol and 55,000 g/mol, is known to present challenges in fiber preparation. In the current study, parameter optimization for PVP possessing molecular weights of 10,000 g/mol and 55,000 g/mol was carried out to obtain nanofibers. The electrospinning technique was utilized for fiber fabrication by optimizing the above-mentioned parameters. SEM analysis was performed to analyze the fiber morphology, and quantitative analysis was performed to correlate the effect of parameters on the fiber morphology. This research study will lead to various applications, such as drug encapsulation for sustained drug release and nanoparticles/nanotubes encapsulation for microwave absorption applications.
Open AccessOptimization of Electrospinning Parameters for Lower Molecular Weight Polymers: A Case Study on Polyvinylpyrrolidone
Polyvinylpyrrolidone (PVP) is a synthetic polymer that holds significance in various fields such as biomedical, medical, and electronics, due to its biocompatibility and exceptional dielectric properties. Electrospinning is the most commonly used tool to fabricate fibers because of its convenience and the wide choice of parameter optimization. Various parameters, including solution molarity, flow rate, voltage, needle gauge, and needle-to-collector distance, can be optimized to obtain the desired morphology of the fibers. Although PVP is commercially available in various molecular weights, PVP with a molecular weight of 130,000 g/mol is generally considered to be the easiest PVP to fabricate fibers with minimal challenges. However, the fiber diameter in this case is usually in the micron regime, which limits the utilization of PVP fibers in fields that require fiber diameters in the nano regime. Generally, PVP with a lower molecular weight, such as 10,000 g/mol and 55,000 g/mol, is known to present challenges in fiber preparation. In the current study, parameter optimization for PVP possessing molecular weights of 10,000 g/mol and 55,000 g/mol was carried out to obtain nanofibers. The electrospinning technique was utilized for fiber fabrication by optimizing the above-mentioned parameters. SEM analysis was performed to analyze the fiber morphology, and quantitative analysis was performed to correlate the effect of parameters on the fiber morphology. This research study will lead to various applications, such as drug encapsulation for sustained drug release and nanoparticles/nanotubes encapsulation for microwave absorption applications.
- Open Access
Electrospun PVA Fibers for Drug Delivery: A Review
Innovation in biomedical science is always a field of interest for researchers. Drug delivery, being one of the key areas of biomedical science, has gained considerable significance. The utilization of simple yet effective techniques such as electrospinning has undergone significant development in the field of drug delivery. Various polymers such as PEG (polyethylene glycol), PLGA (Poly(lactic-co-glycolic acid)), PLA(Polylactic acid), and PCA (poly(methacrylate citric acid)) have been utilized to prepare electrospinning-based drug delivery systems (DDSs). Polyvinyl alcohol (PVA) has recently gained attention because of its biocompatibility, biodegradability, non-toxicity, and ideal mechanical properties as these are the key factors in developing DDSs. Moreover, it has shown promising results in developing DDSs individually and when combined with natural and synthetic polymers such as chitosan and polycaprolactone (PCL). Considering the outstanding properties of PVA, the aim of this review paper was therefore to summarize these recent advances by highlighting the potential of electrospun PVA for drug delivery systems.
Open AccessElectrospun PVA Fibers for Drug Delivery: A Review
Innovation in biomedical science is always a field of interest for researchers. Drug delivery, being one of the key areas of biomedical science, has gained considerable significance. The utilization of simple yet effective techniques such as electrospinning has undergone significant development in the field of drug delivery. Various polymers such as PEG (polyethylene glycol), PLGA (Poly(lactic-co-glycolic acid)), PLA(Polylactic acid), and PCA (poly(methacrylate citric acid)) have been utilized to prepare electrospinning-based drug delivery systems (DDSs). Polyvinyl alcohol (PVA) has recently gained attention because of its biocompatibility, biodegradability, non-toxicity, and ideal mechanical properties as these are the key factors in developing DDSs. Moreover, it has shown promising results in developing DDSs individually and when combined with natural and synthetic polymers such as chitosan and polycaprolactone (PCL). Considering the outstanding properties of PVA, the aim of this review paper was therefore to summarize these recent advances by highlighting the potential of electrospun PVA for drug delivery systems.
- Open Access
- 1 March 2023
- Published by Spandidos Publications in Biomedical Reports
- Vol. 18  (4) , 1-8
Efficacy of PP121 in primary and metastatic non‑small cell lung cancers
Tyrosine kinase inhibitors are a clinically standard treatment option for non‑small cell lung cancers (NSCLCs), the leading cause of cancer‑related deaths in the US. These targeted agents include first, second and third generation tyrosine kinase inhibitors; however, these lack clinical efficacy in the treatment of NSCLC due to intrinsic and acquired resistance. This resistance may be a result of genetic aberrations in oncogenic signaling mediators of divergent pathways. The present study aimed to investigate a novel dual tyrosine kinase and PI3K inhibitor, PP121, as a targeted agent in NSCLC cell lines. The present study co‑cultured PP121 with healthy human astrocytes, a prevalent cell type located in the brain of NSCLC brain metastases. To date, few preclinical studies have examined the efficacy of PP121 as an anticancer agent, and to the best of my knowledge, no previous studies have previously evaluated its therapeutic potential in the treatment of NSCLC. To investigate the clinical heterogeneity of NSCLC, patient‑derived adenocarcinoma (ADC) and squamous cell carcinoma (SCC) xenograft models were used, which exhibited epidermal growth factor receptor (EGFR) mutations and mesenchymal‑epithelial transition (MET) factor amplifications. Notably, both EGFR and MET are known contributors to tyrosine kinase inhibitor resistance; thus, the aforementioned mutations and amplifications enabled the effects of PP121 to be evaluated in these solid tumors. In addition, a co‑cultured model system using both NSCLC cells and astrocytes was employed to assess the effects of PP121 on the invasion of ADC and SCC cells in a multicellular environment. Results of the present study demonstrated that PP121 exerted an antitumorigenic effect in the aforementioned model systems via downregulation of pharmacodynamic targets.
- 1 March 2023
- Published by Spandidos Publications in Biomedical Reports
- Vol. 18  (4) , 1-8
Open AccessEfficacy of PP121 in primary and metastatic non‑small cell lung cancers
Tyrosine kinase inhibitors are a clinically standard treatment option for non‑small cell lung cancers (NSCLCs), the leading cause of cancer‑related deaths in the US. These targeted agents include first, second and third generation tyrosine kinase inhibitors; however, these lack clinical efficacy in the treatment of NSCLC due to intrinsic and acquired resistance. This resistance may be a result of genetic aberrations in oncogenic signaling mediators of divergent pathways. The present study aimed to investigate a novel dual tyrosine kinase and PI3K inhibitor, PP121, as a targeted agent in NSCLC cell lines. The present study co‑cultured PP121 with healthy human astrocytes, a prevalent cell type located in the brain of NSCLC brain metastases. To date, few preclinical studies have examined the efficacy of PP121 as an anticancer agent, and to the best of my knowledge, no previous studies have previously evaluated its therapeutic potential in the treatment of NSCLC. To investigate the clinical heterogeneity of NSCLC, patient‑derived adenocarcinoma (ADC) and squamous cell carcinoma (SCC) xenograft models were used, which exhibited epidermal growth factor receptor (EGFR) mutations and mesenchymal‑epithelial transition (MET) factor amplifications. Notably, both EGFR and MET are known contributors to tyrosine kinase inhibitor resistance; thus, the aforementioned mutations and amplifications enabled the effects of PP121 to be evaluated in these solid tumors. In addition, a co‑cultured model system using both NSCLC cells and astrocytes was employed to assess the effects of PP121 on the invasion of ADC and SCC cells in a multicellular environment. Results of the present study demonstrated that PP121 exerted an antitumorigenic effect in the aforementioned model systems via downregulation of pharmacodynamic targets.
- Open Access
- 1 January 2020
- Published by The Korean Brain Tumor Society, The Korean Society for Neuro-Oncology in Brain Tumor Research and Treatment
- Vol. 8  (1) , 43-52
Inhibition of the Spectraplakin Protein Microtubule Actin Crosslinking Factor 1 Sensitizes Glioblastomas to Radiation
Bonner K, et al. Brain Tumor Res Treat. 2020 Apr;8(1):43-52. https://doi.org/10.14791/btrt.2020.8.e1
- 1 January 2020
- Published by The Korean Brain Tumor Society, The Korean Society for Neuro-Oncology in Brain Tumor Research and Treatment
- Vol. 8  (1) , 43-52
Open AccessInhibition of the Spectraplakin Protein Microtubule Actin Crosslinking Factor 1 Sensitizes Glioblastomas to Radiation
Bonner K, et al. Brain Tumor Res Treat. 2020 Apr;8(1):43-52. https://doi.org/10.14791/btrt.2020.8.e1
- Open Access
- 31 May 2018
- Published by Bio-Byword Scientific Publishing, Pty. Ltd. in Proceedings of Anticancer Research
- Vol. 2  (3)
Nigrospora sphaerica products from the flowering dogwood exhibit antitumorigenic effects via the translational regulator, pS6 ribosomal protein
The utility of diverse species of endophytic fungi as a viable source for drug agents with clinical applicability for the treatment of human diseases continues to expand. In this study we examined secondary metabolites of Nigrospora sphaerica isolated from the flowering dogwood, Cornus florida L., for their anticancer properties on lung cancer and glioblastoma. Molecular identification of N. sphaerica was determined using ITS-rDNA sequence. The expression of translational pathway proteins were examined after exposure to various crude extract concentrations (2µg/ml, 4µg/ml, 8µg/ml) using immunoblotting procedures, while tumor cell migration analysis was performed using boyden chamber assays. Crude N. sphaerica extracts exhibited antiproliferative and antimigratory effects on solid tumors as determined by cell proliferation and cell migration assays, respectively. The antitumorigenic effects of N. sphaerica were as a consequence of negatively regulating the PI3K/Akt/mTOR translational control signaling pathway, a canonical mechanistic axis that contributes to the maintenance and progression of several human cancers. To our knowledge this is the first evidence that demonstrates N. sphaerica from C. florida inhibits tumor cell migration, and thus disease recurrence a major factor in the therapeutic resistance of cancers to chemotherapeutic agents.
- 31 May 2018
- Published by Bio-Byword Scientific Publishing, Pty. Ltd. in Proceedings of Anticancer Research
- Vol. 2  (3)
Open AccessNigrospora sphaerica products from the flowering dogwood exhibit antitumorigenic effects via the translational regulator, pS6 ribosomal protein
The utility of diverse species of endophytic fungi as a viable source for drug agents with clinical applicability for the treatment of human diseases continues to expand. In this study we examined secondary metabolites of Nigrospora sphaerica isolated from the flowering dogwood, Cornus florida L., for their anticancer properties on lung cancer and glioblastoma. Molecular identification of N. sphaerica was determined using ITS-rDNA sequence. The expression of translational pathway proteins were examined after exposure to various crude extract concentrations (2µg/ml, 4µg/ml, 8µg/ml) using immunoblotting procedures, while tumor cell migration analysis was performed using boyden chamber assays. Crude N. sphaerica extracts exhibited antiproliferative and antimigratory effects on solid tumors as determined by cell proliferation and cell migration assays, respectively. The antitumorigenic effects of N. sphaerica were as a consequence of negatively regulating the PI3K/Akt/mTOR translational control signaling pathway, a canonical mechanistic axis that contributes to the maintenance and progression of several human cancers. To our knowledge this is the first evidence that demonstrates N. sphaerica from C. florida inhibits tumor cell migration, and thus disease recurrence a major factor in the therapeutic resistance of cancers to chemotherapeutic agents.
- Open Access
- 26 January 2018
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 19  (2) , 368
Microtubule-Actin Crosslinking Factor 1 and Plakins as Therapeutic Drug Targets
Plakins are a family of seven cytoskeletal cross-linker proteins (microtubule-actin crosslinking factor 1 (MACF), bullous pemphigoid antigen (BPAG1) desmoplakin, envoplakin, periplakin, plectin, epiplakin) that network the three major filaments that comprise the cytoskeleton. Plakins have been found to be involved in disorders and diseases of the skin, heart, nervous system, and cancer that are attributed to autoimmune responses and genetic alterations of these macromolecules. Despite their role and involvement across a spectrum of several diseases, there are no current drugs or pharmacological agents that specifically target the members of this protein family. On the contrary, microtubules have traditionally been targeted by microtubule inhibiting agents, used for the treatment of diseases such as cancer, in spite of the deleterious toxicities associated with their clinical utility. The Research Collaboratory for Structural Bioinformatics (RCSB) was used here to identify therapeutic drugs targeting the plakin proteins, particularly the spectraplakins MACF1 and BPAG1, which contain microtubule-binding domains. RCSB analysis revealed that plakin proteins had 329 ligands, of which more than 50% were MACF1 and BPAG1 ligands and 10 were documented, clinically or experimentally, to have several therapeutic applications as anticancer, anti-inflammatory, and antibiotic agents.
- 26 January 2018
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 19  (2) , 368
Open AccessMicrotubule-Actin Crosslinking Factor 1 and Plakins as Therapeutic Drug Targets
Plakins are a family of seven cytoskeletal cross-linker proteins (microtubule-actin crosslinking factor 1 (MACF), bullous pemphigoid antigen (BPAG1) desmoplakin, envoplakin, periplakin, plectin, epiplakin) that network the three major filaments that comprise the cytoskeleton. Plakins have been found to be involved in disorders and diseases of the skin, heart, nervous system, and cancer that are attributed to autoimmune responses and genetic alterations of these macromolecules. Despite their role and involvement across a spectrum of several diseases, there are no current drugs or pharmacological agents that specifically target the members of this protein family. On the contrary, microtubules have traditionally been targeted by microtubule inhibiting agents, used for the treatment of diseases such as cancer, in spite of the deleterious toxicities associated with their clinical utility. The Research Collaboratory for Structural Bioinformatics (RCSB) was used here to identify therapeutic drugs targeting the plakin proteins, particularly the spectraplakins MACF1 and BPAG1, which contain microtubule-binding domains. RCSB analysis revealed that plakin proteins had 329 ligands, of which more than 50% were MACF1 and BPAG1 ligands and 10 were documented, clinically or experimentally, to have several therapeutic applications as anticancer, anti-inflammatory, and antibiotic agents.
- 9 December 2016
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 50  (1) , 310-316
Microtubule actin cross-linking factor 1, a novel target in glioblastoma
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications
- 9 December 2016
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 50  (1) , 310-316
Microtubule actin cross-linking factor 1, a novel target in glioblastoma
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications
- Open Access
- 20 March 2015
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 12  (1) , 1443-1448
Violacein induces p44/42 mitogen-activated protein kinase-mediated solid tumor cell death and inhibits tumor cell migration
Microbial secondary metabolites have emerged as alternative novel drugs for the treatment of human cancers. Violacein, a purple pigment produced by Chromobacterium violaceum, was investigated in the present study for its anti‑tumor properties in tumor cell lines. Clinically applicable concentrations of violacein were demonstrated to inhibit the proliferative capacity of tumor cell lines according to a crystal violet proliferation assay. The underlying mechanism was the promotion of apoptotic cell death, as indicated by poly(ADP ribose) polymerase cleavage and p44/42 mitogen‑activated protein kinase signaling determined by western blot analysis. Collectively, this provided mechanistic evidence that violacein elicits extracellular-signal regulated kinase‑induced apoptosis via the intrinsic pathway. The anti‑malignant properties of violacein in the present study were further demonstrated by its inhibitory effects on brain tumor cell migration, specifically glioblastomas, one of the most invasive and therapeutically resistant neoplasms in the clinic. Additionally, solid tumors examined in the present study displayed differential cellular responses and sensitivities to violacein as observed by morphologically induced cellular changes that contributed to its anti‑migratory properties. In conclusion, violacein is a novel natural product with the potential to kill several types of human tumor cell lines, as well as prevent disease recurrence by antagonizing cellular processes that contribute to metastatic invasion.
- 20 March 2015
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 12  (1) , 1443-1448
Open AccessViolacein induces p44/42 mitogen-activated protein kinase-mediated solid tumor cell death and inhibits tumor cell migration
Microbial secondary metabolites have emerged as alternative novel drugs for the treatment of human cancers. Violacein, a purple pigment produced by Chromobacterium violaceum, was investigated in the present study for its anti‑tumor properties in tumor cell lines. Clinically applicable concentrations of violacein were demonstrated to inhibit the proliferative capacity of tumor cell lines according to a crystal violet proliferation assay. The underlying mechanism was the promotion of apoptotic cell death, as indicated by poly(ADP ribose) polymerase cleavage and p44/42 mitogen‑activated protein kinase signaling determined by western blot analysis. Collectively, this provided mechanistic evidence that violacein elicits extracellular-signal regulated kinase‑induced apoptosis via the intrinsic pathway. The anti‑malignant properties of violacein in the present study were further demonstrated by its inhibitory effects on brain tumor cell migration, specifically glioblastomas, one of the most invasive and therapeutically resistant neoplasms in the clinic. Additionally, solid tumors examined in the present study displayed differential cellular responses and sensitivities to violacein as observed by morphologically induced cellular changes that contributed to its anti‑migratory properties. In conclusion, violacein is a novel natural product with the potential to kill several types of human tumor cell lines, as well as prevent disease recurrence by antagonizing cellular processes that contribute to metastatic invasion.
- Open Access
- 3 September 2014
- Published by Springer Nature in BMC Research Notes
- Vol. 7  (1) , 1-11
Biological activities of fusarochromanone: a potent anti-cancer agent
Fusarochromanone (FC101) is a small molecule fungal metabolite with a host of interesting biological functions, including very potent anti-angiogenic and direct anti-cancer activity. Herein, we report that FC101 exhibits very potent in-vitro growth inhibitory effects (IC50 ranging from 10nM-2.5 μM) against HaCat (pre-malignant skin), P9-WT (malignant skin), MCF-7 (low malignant breast), MDA-231 (malignant breast), SV-HUC (premalignant bladder), UM-UC14 (malignant bladder), and PC3 (malignant prostate) in a time-course and dose-dependent manner, with the UM-UC14 cells being the most sensitive. FC101 induces apoptosis and an increase in proportion of cells in the sub-G1 phase in both HaCat and P9-WT cell lines as evidenced by cell cycle profile analysis. In a mouse xenograft SCC tumor model, FC101 was well tolerated, non-toxic, and achieved a 30% reduction in tumor size at a dose of 8 mg/kg/day. FC101 is also a potent anti-angiogenenic agent. At nanomolar doses, FC101 inhibits the vascular endothelial growth factor-A (VEGF-A)-mediated proliferation of endothelial cells. Our data presented here indicates that FC101 is an excellent lead candidate for a small molecule anti-cancer agent that simultaneously affects angiogenesis signaling, cancer signal transduction, and apoptosis. Further understanding of the underlying FC101’s molecular mechanism may lead to the design of novel targeted and selective therapeutics, both of which are pursued targets in cancer drug discovery.
- 3 September 2014
- Published by Springer Nature in BMC Research Notes
- Vol. 7  (1) , 1-11
Open AccessBiological activities of fusarochromanone: a potent anti-cancer agent
Fusarochromanone (FC101) is a small molecule fungal metabolite with a host of interesting biological functions, including very potent anti-angiogenic and direct anti-cancer activity. Herein, we report that FC101 exhibits very potent in-vitro growth inhibitory effects (IC50 ranging from 10nM-2.5 μM) against HaCat (pre-malignant skin), P9-WT (malignant skin), MCF-7 (low malignant breast), MDA-231 (malignant breast), SV-HUC (premalignant bladder), UM-UC14 (malignant bladder), and PC3 (malignant prostate) in a time-course and dose-dependent manner, with the UM-UC14 cells being the most sensitive. FC101 induces apoptosis and an increase in proportion of cells in the sub-G1 phase in both HaCat and P9-WT cell lines as evidenced by cell cycle profile analysis. In a mouse xenograft SCC tumor model, FC101 was well tolerated, non-toxic, and achieved a 30% reduction in tumor size at a dose of 8 mg/kg/day. FC101 is also a potent anti-angiogenenic agent. At nanomolar doses, FC101 inhibits the vascular endothelial growth factor-A (VEGF-A)-mediated proliferation of endothelial cells. Our data presented here indicates that FC101 is an excellent lead candidate for a small molecule anti-cancer agent that simultaneously affects angiogenesis signaling, cancer signal transduction, and apoptosis. Further understanding of the underlying FC101’s molecular mechanism may lead to the design of novel targeted and selective therapeutics, both of which are pursued targets in cancer drug discovery.
- Open Access
- 9 July 2014
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 34  (3) , 880-885
Caspase-dependent signaling underlies glioblastoma cell death in response to the fungal metabolite, fusarochromanone
Fungal metabolites continue to show promise as a viable class of anticancer agents. In the present study, we investigated the efficacy of the fungal metabolite, fusarochromanone (FC101), for its antitumor activities in glioblastomas, which have a median survival of less than two years and a poor clinical response to surgical resection, radiation therapy and chemotherapy. Using clinically applicable doses, we demonstrated that FC101 induced glioblastoma apoptotic cell death via caspase dependent signaling, as indicated by the cleavage of poly(ADP-ribose) polymerase, glioblastoma (PARP). FC101 also induced differential reactive oxygen species (ROS) levels in glioblastoma cells, contrasting a defined role of oxidative stress in apoptotic cell death observed with other fungal metabolites. Furthermore, the antitumorigenic effects of FC101 on tumor cell migration were assessed. Cell migration assays revealed that FC101 significantly reduced the migratory capacity of glioblastomas, which are incredibly invasive tumors. Taken together, the present study establishes FC101 as a candidate anticancer agent for the cooperative treatment of glioblastomas.
- 9 July 2014
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 34  (3) , 880-885
Open AccessCaspase-dependent signaling underlies glioblastoma cell death in response to the fungal metabolite, fusarochromanone
Fungal metabolites continue to show promise as a viable class of anticancer agents. In the present study, we investigated the efficacy of the fungal metabolite, fusarochromanone (FC101), for its antitumor activities in glioblastomas, which have a median survival of less than two years and a poor clinical response to surgical resection, radiation therapy and chemotherapy. Using clinically applicable doses, we demonstrated that FC101 induced glioblastoma apoptotic cell death via caspase dependent signaling, as indicated by the cleavage of poly(ADP-ribose) polymerase, glioblastoma (PARP). FC101 also induced differential reactive oxygen species (ROS) levels in glioblastoma cells, contrasting a defined role of oxidative stress in apoptotic cell death observed with other fungal metabolites. Furthermore, the antitumorigenic effects of FC101 on tumor cell migration were assessed. Cell migration assays revealed that FC101 significantly reduced the migratory capacity of glioblastomas, which are incredibly invasive tumors. Taken together, the present study establishes FC101 as a candidate anticancer agent for the cooperative treatment of glioblastomas.